TYME - Tyme Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2300
-0.0300 (-2.38%)
At close: 4:00PM EDT

1.2300 0.00 (0.00%)
After hours: 5:04PM EDT

Stock chart is not supported by your current browser
Previous Close1.2600
Open1.2500
Bid1.2300 x 3100
Ask1.2900 x 1800
Day's Range1.2300 - 1.2600
52 Week Range0.9200 - 4.6420
Volume293,227
Avg. Volume849,769
Market Cap137.7M
Beta (3Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.3220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Trade prices are not sourced from all markets
  • GlobeNewswire12 days ago

    REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

    TYME management will be hosting a conference call on July 9th at 8:30AM EDT to discuss the SM-88 data presented at the ESMO GI Congress. NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile.

  • Tyme Technologies News: Why TYME Stock Is Rocketing
    InvestorPlace15 days ago

    Tyme Technologies News: Why TYME Stock Is Rocketing

    Tyme Technologies (NASDAQ:TYME) stock is skyrocketing on Friday following the company's announcement regarding the latest data from one of its cancer treatments.Source: Shutterstock The U.S. biotechnology company revealed that it had amassed positive updated data regarding its phase 2 study of SM-88, which is a treatment designed to help out patients with pancreatic cancer. This led to trading volume increasing to more than 4.1 million shares, which is more than six times the full-day average.Tyme Technologies said before the open that data from the study of SM-88 as an oral monotherapy revealed that the median overall survival of patients was 6.4 months, which compares favorably next to historical trials that showed survival of 2.0 to 2.5 months. "We believe that these outcomes further justify advancing the development of SM-88," said Chief Medical Officer Giuseppe Del Priore.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients," he added.TYME stock is soaring about 22.5% on Friday afternoon following the news, which brought the price of the stock up to $1.50 per share. The stock had closed at around $1.22 per share by day's end on Wednesday, which is the price it opened at today-the stock market was not open yesterday in observation of Independence Day.The stock is still down more than 50% year-to-date, although the boost helped it move in the right direction. More From InvestorPlace * The Top 8 Tech Stocks of 2019 (So Far) * The 7 Top Small-Cap Stocks Of 2019 * 7 F-Rated Stocks to Sell for Summer * 7 Retail Stocks to Buy That Are Down in 2019 The post Tyme Technologies News: Why TYME Stock Is Rocketing appeared first on InvestorPlace.

  • MarketWatch15 days ago

    Tyme Technologies stock soars on heavy volume after upbeat update to cancer treatment study

    Shares of Tyme Technologies Inc. shot up 31% in active morning trading Friday, after the biotechnology company provided upbeat updated data from its phase 2 study of SM-88 for the treatment of pancreatic cancer. Trading volume swelled to 4.1 million shares, or already more than six-times the full-day average. The company said before the open that data from the study of SM-88 as an oral monotherapy showed that median overall survival of patients was 6.4 months, which compares favorably to historical trials which showed survival of 2.0 to 2.5 months. "We believe that these outcomes further justify advancing the development of SM-88," said Chief Medical Officer Giuseppe Del Priore. "We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients." Despite Friday's rally, the stock was still down 57% year to date, while the iShares Nasdaq Biotechnology ETF has gained 14% and the S&P 500 has advanced 19%.

  • GlobeNewswire15 days ago

    TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile. The data from the TYME-88-Panc study were presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer (ESMO GI) on July 4, 2019 in Barcelona, Spain.

  • Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years?
    Simply Wall St.23 days ago

    Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years?

    In June 2019, Tyme Technologies, Inc. (NASDAQ:TYME) released its most recent earnings announcement, which revealed...

  • GuruFocus.com27 days ago

    Weekly CFO Buys Highlight

    Recent buys from company CFOs

  • GlobeNewswirelast month

    TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer has been selected for poster presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer (ESMO GI) being held on July 3-6, 2019 in Barcelona, Spain. Additional information on the meeting can be found on the ESMO World Congress on Gastrointestinal Cancer website: https://www.worldgicancer.com.

  • GlobeNewswire2 months ago

    TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

    TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (racemetyrosine) Shown to Have Anti-Tumor.

  • The Tyme Technologies (NASDAQ:TYME) Share Price Is Down 83% So Some Shareholders Are Rather Upset
    Simply Wall St.2 months ago

    The Tyme Technologies (NASDAQ:TYME) Share Price Is Down 83% So Some Shareholders Are Rather Upset

    It's not possible to invest over long periods without making some bad investments. But you want to avoid the really...

  • GlobeNewswire2 months ago

    Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Jefferies Global Healthcare Conference in New York on June 7, 2019. The company will present their corporate overview for 2019 with special focus on advances in the science of cancer metabolism and clinical developments for their lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

  • GlobeNewswire2 months ago

    Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company will host a conference call and live webcast on Wednesday, May 29, 2019, at 8:30 A.M. ET to report its fourth quarter and fiscal year 2019 financial and operating results. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties.

  • GlobeNewswire2 months ago

    TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced the initiation of the HopES trial conducted in partnership with The Joseph Ahmed Foundation to better understand and help manage high-risk sarcomas which are ultra-rare cancers with high unmet medical need. "There is an urgent need for more effective treatment options for patients with high-risk sarcomas, including Ewing’s sarcoma,” said Sant Chawla, M.D., Director of the Sarcoma Oncology Research Center, Santa Monica, CA and lead investigator for the HopES trial. "I was encouraged by the initial clinical trial data for SM-88 in metastatic sarcomas.  This study has the potential to provide a new treatment option for patients with Ewing’s sarcoma who do not reach complete remission with first line treatment and patients with other sarcomas after progression.

  • GlobeNewswire2 months ago

    TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers

    Tyme Technologies, Inc.  (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that it has received notification that the United States Patent and Trademark Office (USPTO) intends to issue another patent related to TYME’s technology platform. U.S. Patent No.10,307,465 will be directed to methods for treating cancer using tyrosine hydroxylase inhibitors, such as TYME’s lead compound SM-88 (racemetyrosine), to make cancer cells more accessible to oxidative stress.

  • GlobeNewswire2 months ago

    Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will participate at the Oppenheimer Oncology Insight Summit in New York on Thursday, May 16, 2019. In one-on-one settings, the company will present its corporate overview for 2019 with special focus on advances in the science of cancer metabolism and clinical developments in lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers. The presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com.

  • GlobeNewswire3 months ago

    Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2019 at the BioNJ 9th Annual BioPartnering Conference on Wednesday, May 8, 2019. Co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, the conference brings together biopharmaceutical companies, investors, and academic collaborators across the Northeast to Mid-Atlantic states. Tyme Technologies, Inc., is an emerging biotechnology company developing cancer metabolism-based therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

  • GlobeNewswire3 months ago

    Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the SunTrust Robinson Humphrey’s 5th Annual Life sciences Summit in New York on May 7th. In one-on-one settings, the company will present its corporate overview for 2019 with special focus on advances in science and clinical developments in oncology and orphan diseases.

  • GlobeNewswire3 months ago

    TYME Announces USAN Approval of Generic Name “Racemetyrosine” for SM-88

    Tyme Technologies, Inc.  (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that the United States Adopted Name (USAN) Council recently granted “racemetyrosine” as the generic name for SM-88, TYME’s lead pipeline candidate. The purpose of the United States Adopted Names Council is to serve the health professions in the United States by selecting simple, informative, and unique generic names for therapies by establishing logical nomenclature classifications based on pharmacological and/or chemical relationships.

  • GlobeNewswire3 months ago

    TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the results of its first human study, completed as of September 15, 2017 and designed to evaluate the safety, tolerability and efficacy of SM-88 in patients with advanced metastatic cancers, was published online on March 30th 2019 in the peer-reviewed journal Investigational New Drugs.

  • GlobeNewswire4 months ago

    TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced the closing of its underwritten registered offering with a group of three existing and one new investors resulting in gross proceeds of $12 million. TYME is in the process of finalizing a randomized pivotal trial protocol amendment for use of SM-88 in third-line pancreatic cancer.

  • GlobeNewswire4 months ago

    TYME Announces Dismissal of Class Action Lawsuit

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) announced the consolidated class action complaint filed in the United States District Court for the Southern District of New York (Case No. 1:19-cv-00843) was voluntarily dismissed, without prejudice against all the defendants, by the plaintiff and his counsel on March 28, 2019. TYME had previously stated the class action allegations were meritless and is pleased that plaintiff and his counsel agreed to voluntarily withdraw the case. The case was never formally certified as a class action lawsuit.

  • GlobeNewswire4 months ago

    Tyme Technologies Announces Pricing of its $12 Million Registered Offering

    Tyme Technologies, Inc. (TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value $0.0001 per share, and warrants to purchase 8 million shares of its common stock at a combined purchase price of $1.50 per share of common stock and accompanying warrant, resulting in gross proceeds of approximately $12 million. The warrants will be exercisable beginning six months after issuance at a price of $2.00 per share of common stock and have a term of five years commencing on the date of issuance. The shares of common stock and the warrants will be immediately separable and will be issued separately.

  • GlobeNewswire4 months ago

    SHAREHOLDER ALERT: VALE TYME UXIN UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, March 28, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.

  • ACCESSWIRE4 months ago

    DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / March 28, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. ("Tyme" or "the Company") (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between June 22, 2018 and November 19, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before March 29, 2019.

  • GlobeNewswire4 months ago

    SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME  

    NEW YORK, March 28, 2019 -- Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ: TYME) and.

  • ACCESSWIRE4 months ago

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, GE and AVP

    CEDARHURST, NY / ACCESSWIRE / March 28, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.